OLVIG
RETA

Oliver Lagore Vanvalin Investment Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-107
Closed -$4.07K – 746
2022
Q4 		$4.07K Buy
+107
New +$3.68K ﹤0.01% 493

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's RETA Position: Q1 2023 in Review

Oliver Lagore Vanvalin Investment Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 107 shares — an estimated $4.07K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in RETA in Q4 2022 and held it in 1 quarter. The position peaked at $4.07K in Q4 2022. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

  • Oliver Lagore Vanvalin Investment Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 107 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $4.07K.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 1 quarter.
  • Oliver Lagore Vanvalin Investment Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.07K in Q4 2022.
  • 205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q1 2023, filed 20 Jun 2023.